CD22 and diffuse large B-cell lymphoma: This study firstly reported the safety, efficacy as well as the survival of tandem CD19/CD22 CAR-T therapy with DAC containing lymphodepletion regimen in 33 R/R DLBCL and addressed the additional benefit of DAC in CAR-T treated R/R DLBCL patients.